Exceptional antitumor responses beyond immune checkpoint inhibition in non-small cell lung cancer patients: insights into optimal therapy sequencing

Lung cancer represents the leading cause of cancer mortality, with an estimated of 222,500 new cases and 155,870 deaths in the United States in 2017 (1). The majority of patients present with metastatic disease at the time of initial diagnosis, with 5-year survival rates of 2% (2).